Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2026)

Entrada Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $121000.0 for Q4 2025.

• In Q4 2025, Capital Expenditures fell 97.67% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at -$108000.0 (down 103.43% YoY), while the FY2024 annual figure was $3.2 million, down 43.75% from the prior year.
• Capital Expenditures for Q4 2025 stood at $121000.0, up from -$36000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $8.6 million in Q1 2023, with the low at -$7.7 million in Q2 2023.
• The 5-year median for Capital Expenditures is $256000.0 (2022), against an average of $672000.0.
• Peak annual rise in Capital Expenditures reached 2107.93% in 2023, while the deepest fall reached 1895.88% in 2023.
• Entrada Therapeutics' Capital Expenditures stood at $2.7 million in 2021, then plunged by 178.7% to -$2.1 million in 2022, then jumped by 146.68% to $976000.0 in 2023, then soared by 432.99% to $5.2 million in 2024, then sank by 97.67% to $121000.0 in 2025.
• Business Quant data shows TRDA's Capital Expenditures at $121000.0 in Q4 2025, -$36000.0 in Q3 2025, and -$193000.0 in Q2 2025.